Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

L van Andel; H Rosing; Z Zhang; L Hughes; V Kansra; M Sanghvi; M M Tibben; A Gebretensae; J H M Schellens; J H Beijnen

doi:10.1007/s00280-017-3474-7

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients

Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

Authors

L van Andel¹, H Rosing², Z Zhang³, L Hughes³, V Kansra³, M Sanghvi⁴, M M Tibben², A Gebretensae², J H M Schellens^{5

6}, J H Beijnen^{2

6}

Affiliations

¹ Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, PO Box 90440, 1006 BK, Amsterdam, The Netherlands. [email protected].
² Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, PO Box 90440, 1006 BK, Amsterdam, The Netherlands.
³ TESARO, Inc., Waltham, MA, USA.
⁴ Xceleron, Inc., A Pharmaron Company, Germantown, MD, USA.
⁵ Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁶ Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

Abstract

The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients'', written by L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens and J. H. Beijnen, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 17th October 2017 without open access.

Publication types

Published Erratum